StocksMedium•4 November 2026•
1 min read
Pfizer Raises 2026 Guidance After Q3 Revenue Beats Estimates at $16.58B
Key Facts
1Pfizer delivered Q3 2026 revenue of $16.58B, beating consensus estimates.
2The company raised its full-year 2026 revenue guidance to a range of $62B to $64B.
3Non-COVID portfolio grew 7% operationally, offsetting steep declines in COVID-related product sales.
Pfizer delivered Q3 2026 revenue of $16.58 billion, surpassing consensus estimates. Seeking Alpha reported that the company raised its full-year 2026 revenue guidance to a range of $62 billion to $64 billion, marking its second upward revision this year.
The non-COVID product portfolio grew 7% operationally, helping to offset steep declines in COVID-related product sales. Pfizer (PFE) closed at $30 on November 3, 2026, having traded between a low of $29.89 and a high of $31.06 during that session.